Raphael Pharmaceutical Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
RAPHStored price and day change unavailable
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Balance Sheets
| As of March 31, | As of December 31, | |
|---|---|---|
| 2026 | 2025 | |
| (Unaudited) | (Audited) | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $1 | $45 |
| Other current assets | - | 6 |
| Total current assets | 1 | 51 |
| Fixed assets, net | 2 | 2 |
| Total assets | $3 | $53 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Other accounts payables and accrued expenses | 527 | 506 |
| Short-term credit from related party | 37 | 34 |
| Payable to related party | 1,101 | 946 |
| Total current liabilities | 1,665 | 1486 |
| Stockholders’ equity (deficit): | ||
| Common stock, $0.01 par value: | ||
| Authorized: 50,000,000 shares at March 31, 2026 and December 31, 2025; | ||
| Issued and outstanding: 20,176,418 at March 31, 2026 and at December 31, 2025, respectively; | 202 | 202 |
| Additional paid-in capital | 8,533 | 8,533 |
| Accumulated deficit | (10,397) | (10,168) |
| Total stockholders’ equity (deficit) | (1,662) | (1,433) |
| Total liabilities and stockholders’ equity (deficit) | $3 | $53 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.